Potential Breakthrough for Aligos Therapeutics in Hepatitis B Treatment
AI Prediction of Aligos Therapeutics, Inc. Common Stock (ALGS)
Aligos Therapeutics, focused on liver and viral diseases, is nearing key Phase 2 interim analysis for its lead asset, ALG-000184, targeting chronic hepatitis B. Positive trial outcomes could significantly impact its stock value.
Aligos Therapeutics, a clinical-stage biopharmaceutical company, is at a pivotal stage with its lead asset, ALG-000184, a potential first-/best-in-class therapy for chronic hepatitis B virus (HBV) infection. The company is preparing for interim analyses from its global Phase 2 B-SUPREME study in 1H and 2H 2026. These milestones are critical as they will provide early insights into the efficacy and safety of ALG-000184, potentially setting the stage for advanced clinical trials and strategic partnerships. The market for HBV treatments is substantial, underscoring significant commercial potential for effective therapies. Investors should closely monitor these developments, as positive data could lead to substantial share price appreciation.
ALGS Report Information
Prediction Date2026-03-27
Close @ Prediction$7.04
Mkt Cap41m
IPO Date2020-10-16
AI-derived Information
Recent News for ALGS
- Mar 5, 8:00 am — Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
- Feb 26, 8:00 am — Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 (GlobeNewswire)
- Feb 23, 8:00 am — Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) (GlobeNewswire)
- Jan 30, 8:00 am — Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Jan 21, 8:00 am — Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates (GlobeNewswire)
- Jan 13, 8:00 am — Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer (GlobeNewswire)
- Dec 12, 8:00 am — Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Dec 11, 8:00 am — Aligos Therapeutics Presents Positive Data at HEP-DART 2025 (GlobeNewswire)
- Nov 14, 8:00 am — Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Nov 10, 8:00 am — Aligos Therapeutics Presents Positive Data at The Liver Meeting 2025 (GlobeNewswire)
- Nov 6, 8:30 am — Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results (GlobeNewswire)
- Nov 4, 8:30 am — Aligos Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
NDAPR (News-Driven AI Prediction Revision) events for ALGS
No NDAPR events found.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest